Beibei Fu
Impact in
- Aging top 10%
- Geriatrics and Gerontology top 5%
- Sirtuins and Resveratrol in Medicine
Papers in
-
- Ubiquitin and proteasome pathways 3
-
- SARS-CoV-2 and COVID-19 Research 6
- COVID-19 Clinical Research Studies 3
- Co-authors
- Haibo Wu (31 shared papers)Jiamin Zhao (7 shared papers)Wei Peng (5 shared papers)Xiaoyuan Lin (20 shared papers)Jingcheng Zhang (4 shared papers)Weiwei Xue (9 shared papers)Songna Yin (4 shared papers)Bing‐Hua Jiang (1 shared paper)
In The Last Decade
Beibei Fu
61 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 114
- Aging 37
- Geriatrics and Gerontology 64
- Infectious Diseases 256
- Endocrine and Autonomic Systems 75
- Cancer Research 128
Countries citing papers authored by Beibei Fu
This map shows the geographic impact of Beibei Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beibei Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beibei Fu more than expected).
Fields of papers citing papers by Beibei Fu
This network shows the impact of papers produced by Beibei Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beibei Fu. The network helps show where Beibei Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Beibei Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 156 | |
| 2 | 2016 | 140 | |
| 3 | 2021 | 135 | |
| 4 | 2021 | 95 | |
| 5 | 2017 | 78 | |
| 6 | 2017 | 75 | |
| 7 | 2017 | 67 | |
| 8 | 2020 | 46 | |
| 9 | 2016 | 40 | |
| 10 | 2022 | 38 | |
| 11 | 2023 | 34 | |
| 12 | 2017 | 32 | |
| 13 | 2022 | 31 | |
| 14 | 2022 | 26 | |
| 15 | 2021 | 25 | |
| 16 | 2024 | 21 | |
| 17 | 2017 | 21 | |
| 18 | 2015 | 18 | |
| 19 | 2023 | 18 | |
| 20 | 2020 | 17 |
About Beibei Fu
Beibei Fu is a scholar working on Molecular Biology, Infectious Diseases, Oncology, Pulmonary and Respiratory Medicine and Immunology, having authored 61 papers that have together received 1.4k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (6 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Gallbladder and Bile Duct Disorders (4 papers), Ubiquitin and proteasome pathways (3 papers), interferon and immune responses (3 papers), HER2/EGFR in Cancer Research (3 papers), COVID-19 Clinical Research Studies (3 papers) and Pediatric Hepatobiliary Diseases and Treatments (3 papers). The work is most often cited by research in Aging (37 citations), Geriatrics and Gerontology (64 citations), Infectious Diseases (256 citations), Endocrine and Autonomic Systems (75 citations) and Cancer Research (128 citations). Beibei Fu has collaborated with scholars based in China, Egypt and Germany. Frequent co-authors include Haibo Wu, Jiamin Zhao, Wei Peng, Xiaoyuan Lin, Jingcheng Zhang, Weiwei Xue, Songna Yin, Bing‐Hua Jiang, Jing Fang and Jing Xue. Their work appears in journals such as mBio, Journal of Chemical Information and Modeling, Biomedicine & Pharmacotherapy, Molecular Cancer Therapeutics and International Immunopharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.